Charles River Laboratories International (NYSE: CRL ) is expected to report Q4 earnings on Feb. 13. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Charles River Laboratories International's revenues will wane -3.4% and EPS will wane -13.0%.
The average estimate for revenue is $281.1 million. On the bottom line, the average EPS estimate is $0.60.
Last quarter, Charles River Laboratories International booked revenue of $278.7 million. GAAP reported sales were 0.4% higher than the prior-year quarter's $277.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.65. GAAP EPS of $0.46 for Q3 were 24% higher than the prior-year quarter's $0.37 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 33.5%, 10 basis points better than the prior-year quarter. Operating margin was 14.8%, 140 basis points better than the prior-year quarter. Net margin was 7.9%, 110 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $1.13 billion. The average EPS estimate is $2.71.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Charles River Laboratories International is outperform, with an average price target of $39.91.
Looking for alternatives to Charles River Laboratories International? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Charles River Laboratories International to My Watchlist.